Department of Neurodegenerative Disease, University College London Institute of Neurology, Queen Square, London, UK.
EMBO J. 2011 Jul 8;30(15):3065-77. doi: 10.1038/emboj.2011.224.
Prion diseases are associated with the conversion of cellular prion protein (PrP(C)) to toxic β-sheet isoforms (PrP(Sc)), which are reported to inhibit the ubiquitin-proteasome system (UPS). Accordingly, UPS substrates accumulate in prion-infected mouse brains, suggesting impairment of the 26S proteasome. A direct interaction between its 20S core particle and PrP isoforms was demonstrated by immunoprecipitation. β-PrP aggregates associated with the 20S particle, but did not impede binding of the PA26 complex, suggesting that the aggregates do not bind to its ends. Aggregated β-PrP reduced the 20S proteasome's basal peptidase activity, and the enhanced activity induced by C-terminal peptides from the 19S ATPases or by the 19S regulator itself, including when stimulated by polyubiquitin conjugates. However, the 20S proteasome was not inhibited when the gate in the α-ring was open due to a truncation mutation or by association with PA26/PA28. These PrP aggregates inhibit by stabilising the closed conformation of the substrate entry channel. A similar inhibition of substrate entry into the proteasome may occur in other neurodegenerative diseases where misfolded β-sheet-rich proteins accumulate.
朊病毒疾病与细胞朊蛋白(PrP(C))转化为有毒的β-折叠异构体(PrP(Sc))有关,据报道,这种转化会抑制泛素-蛋白酶体系统(UPS)。因此,在感染朊病毒的小鼠大脑中,UPS 底物会积累,这表明 26S 蛋白酶体受到了损害。通过免疫沉淀实验证实了其 20S 核心颗粒与 PrP 异构体之间的直接相互作用。β-PrP 聚集体与 20S 颗粒相关联,但不阻碍 PA26 复合物的结合,这表明聚集体不与其末端结合。聚集的β-PrP 降低了 20S 蛋白酶体的基础肽酶活性,并且增强了由 19S ATP 酶的 C 端肽或由 19S 调节剂本身诱导的活性,包括当被多聚泛素缀合物刺激时。然而,当由于截断突变或与 PA26/PA28 相关联而导致 α 环中的门打开时,20S 蛋白酶体不会被抑制。这些 PrP 聚集体通过稳定底物进入通道的封闭构象来抑制。在其他神经退行性疾病中,错误折叠的富含β-折叠的蛋白质积累,可能会发生类似的进入蛋白酶体的底物抑制。